Compare Stocks: SNTI, ALPS, EDSA, and APLM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.27 -8.7%	$0.52	$0.23 ▼ $15.00	$49.19M	-0.1	51,412 shs	59,473 shs
APLM Apollomics	$23.70 -0.9%	$18.63	$3.66 ▼ $42.12	$52.53M	1.46	32,046 shs	7,938 shs
EDSA Edesa Biotech	$5.75 +0.7%	$6.32	$0.72 ▼ $20.32	$55.05M	1.08	59,608 shs	107,682 shs
SNTI Senti Biosciences	$0.46 +7.6%	$0.70	$0.33 ▼ $2.88	$13.40M	2.1	197,311 shs	207,103 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	-8.66%	-24.58%	-42.85%	-61.43%	+26,999,900.00%
APLM Apollomics	-0.91%	+38.93%	+25.67%	+61.95%	+338.84%
EDSA Edesa Biotech	+0.70%	+8.49%	-1.20%	-47.10%	+147.84%
SNTI Senti Biosciences	+7.65%	+23.40%	+6.73%	-52.95%	-71.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.27 -8.7%	$0.52	$0.23 ▼ $15.00	$49.19M	-0.1	51,412 shs	59,473 shs
APLM Apollomics	$23.70 -0.9%	$18.63	$3.66 ▼ $42.12	$52.53M	1.46	32,046 shs	7,938 shs
EDSA Edesa Biotech	$5.75 +0.7%	$6.32	$0.72 ▼ $20.32	$55.05M	1.08	59,608 shs	107,682 shs
SNTI Senti Biosciences	$0.46 +7.6%	$0.70	$0.33 ▼ $2.88	$13.40M	2.1	197,311 shs	207,103 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	-8.66%	-24.58%	-42.85%	-61.43%	+26,999,900.00%
APLM Apollomics	-0.91%	+38.93%	+25.67%	+61.95%	+338.84%
EDSA Edesa Biotech	+0.70%	+8.49%	-1.20%	-47.10%	+147.84%
SNTI Senti Biosciences	+7.65%	+23.40%	+6.73%	-52.95%	-71.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPS ALPS Group Inc Ordinary Share	1.00	Sell	N/A	N/A
APLM Apollomics	1.00	Sell	N/A	N/A
EDSA Edesa Biotech	2.67	Moderate Buy	$5.00	-13.04% Downside
SNTI Senti Biosciences	2.75	Moderate Buy	$10.00	2,059.83% Upside

Current Analyst Ratings Breakdown

Latest SNTI, ALPS, EDSA, and APLM Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	SNTI Senti Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	ALPS ALPS Group Inc Ordinary Share	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	EDSA Edesa Biotech	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2026	EDSA Edesa Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/23/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/4/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPS ALPS Group Inc Ordinary Share	$4.86M	9.24	N/A	N/A	($3.10) per share	-0.09
APLM Apollomics	$8.50M	6.13	N/A	N/A	($2.89) per share	-8.20
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.04 per share	N/A
SNTI Senti Biosciences	$20K	721.12	N/A	N/A	($0.11) per share	-4.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPS ALPS Group Inc Ordinary Share	-$2.01M	$0.33	0.82	N/A	N/A	N/A	N/A	N/A	N/A
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/24/2026 (Estimated)
EDSA Edesa Biotech	-$7.19M	-$1.69	N/A	N/A	N/A	N/A	-560.22%	-105.74%	N/A
SNTI Senti Biosciences	-$61.44M	-$1.77	N/A	N/A	N/A	N/A	-1,629.80%	-119.72%	N/A

Latest SNTI, ALPS, EDSA, and APLM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	SNTI Senti Biosciences	-$0.33	-$0.41	-$0.08	-$0.41	N/A	$0.02 million
8/13/2026	Q3 2026	EDSA Edesa Biotech	-$0.4350	-$0.60	-$0.1650	-$0.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPS ALPS Group Inc Ordinary Share	N/A	N/A	N/A	N/A	N/A
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPS ALPS Group Inc Ordinary Share	N/A	0.36	0.27
APLM Apollomics	N/A	0.96	0.96
EDSA Edesa Biotech	N/A	2.76	2.76
SNTI Senti Biosciences	N/A	0.83	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPS ALPS Group Inc Ordinary Share	27.90%
APLM Apollomics	19.13%
EDSA Edesa Biotech	5.50%
SNTI Senti Biosciences	25.70%

Insider Ownership

Company	Insider Ownership
ALPS ALPS Group Inc Ordinary Share	25.52%
APLM Apollomics	N/A
EDSA Edesa Biotech	24.40%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPS ALPS Group Inc Ordinary Share	N/A	166.40 million	123.94 million	N/A
APLM Apollomics	45	2.20 million	N/A	Not Optionable
EDSA Edesa Biotech	20	9.64 million	7.29 million	Not Optionable
SNTI Senti Biosciences	4	31.15 million	30.17 million	Not Optionable

SNTI, ALPS, EDSA, and APLM Headlines

Recent News About These Companies

MacroGenics (NASDAQ:MGNX) vs. Senti Biosciences (NASDAQ:SNTI) Head-To-Head Survey

August 15, 2026 | americanbankingnews.com

Senti Biosciences Holdings Inc

August 11, 2026 | cnn.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next ...

July 15, 2026 | markets.businessinsider.com

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

July 15, 2026 | globenewswire.com

Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure

May 16, 2026 | tipranks.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important ...

May 14, 2026 | markets.businessinsider.com $https://markets.businessinsider.com/news/stocks/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-and-durability-1036155933$

Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia

May 14, 2026 | quiverquant.comQ

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

May 14, 2026 | globenewswire.com

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

May 14, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/05/14/3294958/0/en/senti-biosciences-holdings-announces-positive-fda-rmat-meeting-on-registrational-clinical-and-cmc-strategy-for-senti-202-in-relapsed-refractory-aml-along-with-important-efficacy-an.html$

Senti Biosciences Holdings Inc.

May 13, 2026 | barrons.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | markets.businessinsider.com

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 | globenewswire.com

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

April 1, 2026 | globenewswire.com

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

March 27, 2026 | globenewswire.com

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

March 23, 2026 | globenewswire.com

Senti Biosciences Amends Lease, Restructures GeneFab Sublease

March 19, 2026 | tipranks.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | tmcnet.com

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

March 3, 2026 | globenewswire.com

Senti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care Conference

February 24, 2026 | quiverquant.comQ

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

February 24, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, ALPS, EDSA, and APLM Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.27 -0.03 (-8.66%)

Closing price 08/19/2026 03:58 PM Eastern

Extended Trading

$0.29 +0.02 (+7.41%)

As of 07:15 AM Eastern

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

Apollomics NASDAQ:APLM

$23.70 -0.22 (-0.91%)

Closing price 08/19/2026 03:59 PM Eastern

Extended Trading

$23.63 -0.07 (-0.30%)

As of 08/19/2026 07:30 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Edesa Biotech NASDAQ:EDSA

$5.75 +0.04 (+0.70%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$4.93 -0.82 (-14.17%)

As of 07:16 AM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Senti Biosciences NASDAQ:SNTI

$0.46 +0.03 (+7.65%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$0.47 +0.01 (+1.94%)

As of 07:10 AM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNTI, ALPS, EDSA, and APLM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNTI, ALPS, EDSA, and APLM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNTI, ALPS, EDSA, and APLM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, ALPS, EDSA, and APLM Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

Apollomics NASDAQ:APLM

Edesa Biotech NASDAQ:EDSA

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SNTI, ALPS, EDSA, and APLM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SNTI, ALPS, EDSA, and APLM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SNTI, ALPS, EDSA, and APLM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, ALPS, EDSA, and APLM Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

Apollomics NASDAQ:APLM

Edesa Biotech NASDAQ:EDSA

Senti Biosciences NASDAQ:SNTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools